The PERSEPHONE trial: Duration of trastuzumab with chemotherapy in women with HER2-positive early breast cancer.
Helena Margaret Earl
Honoraria - advisory board
David A. Cameron
Honoraria - Advisory Boards
David Miles
No relevant relationships to disclose
Andrew M. Wardley
No relevant relationships to disclose
Emma Ogburn
No relevant relationships to disclose
A-L Vallier
No relevant relationships to disclose
Shrushma Loi
No relevant relationships to disclose
Helen B Higgins
No relevant relationships to disclose
Louise Hiller
No relevant relationships to disclose
Janet A Dunn
Honoraria - Advisory Boards